BioXcel Therapeutics, Inc. Investment Income, Interest
BioXcel Therapeutics, Inc. (BTAI) reported Investment Income, Interest of $131.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-13
- BioXcel Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $131.00K, a 43.04% decline year-over-year.
- BioXcel Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $211.00K, a 24.37% decline year-over-year.
- BioXcel Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $321.00K, a 12.77% decline year-over-year.
- BioXcel Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $236.00K, a 61.69% decline year-over-year.
- BioXcel Therapeutics, Inc. investment income, interest for fiscal 2025 was $1.07M, a 59.03% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. investment income, interest for fiscal 2024 was $2.60M, a 53.94% decline from fiscal 2023.
- BioXcel Therapeutics, Inc. investment income, interest for fiscal 2023 was $5.65M, a 123.46% increase from fiscal 2022.
- BioXcel Therapeutics, Inc. investment income, interest for fiscal 2022 was $2.53M, a 5645.45% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $131.00K 10-Q · filed 2026-08-13 | $342.00K 10-Q · filed 2026-08-13 | $663.00K derived: sum of 3 quarters · filed 2026-08-13 | $899.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $211.00K 10-Q · filed 2026-05-15 | $532.00K derived: sum of 2 quarters · filed 2026-05-15 | $768.00K derived: sum of 3 quarters · filed 2026-05-15 | $998.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $321.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $557.00K derived: sum of 2 quarters · filed 2026-03-27 | $787.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.07M 10-K · filed 2026-03-27 |
| 2025-09-30 | $236.00K 10-Q · filed 2025-11-12 | $466.00K derived: sum of 2 quarters · filed 2026-08-13 | $745.00K 10-Q · filed 2025-11-12 | $1.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $230.00K 10-Q · filed 2026-08-13 | $509.00K 10-Q · filed 2026-08-13 | $877.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.49M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $279.00K 10-Q · filed 2026-05-15 | $647.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.26M derived: sum of 3 quarters · filed 2026-05-15 | $1.93M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $368.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $984.00K derived: sum of 2 quarters · filed 2026-03-27 | $1.66M derived: sum of 3 quarters · filed 2026-03-27 | $2.60M 10-K · filed 2026-03-27 |
| 2024-09-30 | $616.00K 10-Q · filed 2025-11-12 | $1.29M derived: sum of 2 quarters · filed 2025-11-12 | $2.23M 10-Q · filed 2025-11-12 | $3.18M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $671.00K 10-Q · filed 2025-08-12 | $1.62M 10-Q · filed 2025-08-12 | $2.56M derived: sum of 3 quarters · filed 2025-08-12 | $3.63M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $947.00K 10-Q · filed 2025-05-12 | $1.89M derived: sum of 2 quarters · filed 2025-05-12 | $2.96M derived: sum of 3 quarters · filed 2025-05-12 | $4.58M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $946.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $2.01M derived: sum of 2 quarters · filed 2025-03-28 | $3.63M derived: sum of 3 quarters · filed 2025-03-28 | $5.65M 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.07M 10-Q · filed 2024-11-14 | $2.69M derived: sum of 2 quarters · filed 2024-11-14 | $4.70M 10-Q · filed 2024-11-14 | $6.19M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $1.62M 10-Q · filed 2024-08-06 | $3.64M 10-Q · filed 2024-08-06 | $5.12M derived: sum of 3 quarters · filed 2024-08-06 | $5.95M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $2.02M 10-Q · filed 2024-05-09 | $3.50M derived: sum of 2 quarters · filed 2024-05-09 | $4.32M derived: sum of 3 quarters · filed 2024-05-09 | $4.53M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $2.31M derived: sum of 2 quarters · filed 2024-03-22 | $2.51M derived: sum of 3 quarters · filed 2024-03-22 | $2.53M 10-K · filed 2024-03-22 |
| 2022-09-30 | $823.00K 10-Q · filed 2023-11-14 | $1.03M derived: sum of 2 quarters · filed 2023-11-14 | $1.04M 10-Q · filed 2023-11-14 | $1.05M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $204.00K 10-Q · filed 2023-08-14 | $219.00K 10-Q · filed 2023-08-14 | $231.00K derived: sum of 3 quarters · filed 2023-08-14 | $243.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $15.00K 10-Q · filed 2023-05-09 | $27.00K derived: sum of 2 quarters · filed 2023-05-09 | $39.00K derived: sum of 3 quarters · filed 2023-05-09 | $49.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $24.00K derived: sum of 2 quarters · filed 2023-03-16 | $34.00K derived: sum of 3 quarters · filed 2023-03-16 | $44.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $12.00K 10-Q · filed 2021-11-10 | $22.00K derived: sum of 2 quarters · filed 2022-08-11 | $32.00K 10-Q · filed 2021-11-10 | $47.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-06-30 | $10.00K 10-Q · filed 2022-08-11 | $20.00K 10-Q · filed 2022-08-11 | $35.00K derived: sum of 3 quarters · filed 2022-08-11 | $55.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $10.00K 10-Q · filed 2022-05-09 | $25.00K derived: sum of 2 quarters · filed 2022-05-09 | $45.00K derived: sum of 3 quarters · filed 2022-05-09 | $73.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $35.00K derived: sum of 2 quarters · filed 2022-03-11 | $63.00K derived: sum of 3 quarters · filed 2022-03-11 | $155.00K 10-K · filed 2022-03-11 |
| 2020-09-30 | $20.00K 10-Q · filed 2021-11-10 | $48.00K derived: sum of 2 quarters · filed 2021-11-10 | $140.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $28.00K 10-Q · filed 2021-08-10 | $119.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $91.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |